CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease

Genome editing is potentially a curative technique available to all individuals with β-hemoglobinopathies, including sickle cell disease (SCD). Fetal hemoglobin (HbF) inhibits sickle hemoglobin (HbS) polymerization, and it is well described that naturally occurring hereditary persistence of HbF (HPF...

Descripción completa

Detalles Bibliográficos
Autores principales: Demirci, Selami, Leonard, Alexis, Essawi, Khaled, Tisdale, John F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526756/
https://www.ncbi.nlm.nih.gov/pubmed/34729375
http://dx.doi.org/10.1016/j.omtm.2021.09.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526756/
https://www.ncbi.nlm.nih.gov/pubmed/34729375
http://dx.doi.org/10.1016/j.omtm.2021.09.010

Ejemplares similares